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ABSTRACT
To date, targeted therapy for pancreatic ductal adenocarcinoma (PDAC) remains
largely unsuccessful in the clinic. Current genomics-based technologies are unable
to reflect the quantitative, dynamic signaling changes in the tumor, and require
larger tumor samples that are difficult to obtain in PDAC patients. Therefore, a
highly sensitive functional tool that can reliably and comprehensively inform intratumoral signaling events is direly needed to guide treatment decision. We tested
the utility of a highly sensitive proteomics-based functional diagnostic platform,
Collaborative Enzyme Enhanced Reactive-immunoassay (CEERTM), on fine-needle
aspiration (FNA) samples obtained from 102 patients with radiographically-evident
pancreatic tumors. Two FNA passes were collected from each patient, hybridized
to customized chips coated with an array of capture antibodies, and detected using
two enzyme-conjugated antibodies which emit quantifiable signals. We demonstrate
that this technique is highly sensitive in detecting total and phosphorylated forms
of multiple signaling molecules in FNA specimens, with reasonable correlation of
marker intensities between two different FNA passes. Notably, signals of several
markers were significantly higher in PDAC compared to non-cancerous samples. In
PDAC samples, we found high total c-Met signal to be associated with poor survival,
and confirmed this finding using an independent PDAC tissue microarray.

INTRODUCTION

the aggressive nature of PDAC is a complex, deregulated
signaling circuitry woven by several genetic alterations
such as oncogenic mutations of KRas, overexpression
of EGFR/HER family members, and loss of key tumor
suppressors including p53, CDKN2A and SMAD4,
which cooperatively enhance the survival of PDAC cells
and resist the killing effect of therapies [2-5]. Although
targeting these deregulated signaling events holds
promise to improve the outcome of PDAC patients,

To date, the prognosis for pancreatic ductal
adenocarcinoma (PDAC) remains dismal. Complete
surgical resection offers the only chance for cure, but is
limited to a small fraction of patients who are diagnosed
at early stage. Even then, most patients who undergo
seemingly successful resection eventually succumb to
disease relapse despite adjuvant treatment [1]. Underlying
www.impactjournals.com/oncotarget
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clinical success remains limited [6]. The advent of next
generation sequencing technologies has helped realize
the goal of “personalized oncology” by allowing patients
to be allocated to clinical trials tailored towards genomic
alterations found in their tumors [7]. These techniques,
despite being promising, have met with their own set
of challenges, which include low tumor cellularity
that is typical of PDAC, tumor heterogeneity, clonal
evolution, and importantly, frequent discordance between
genotype and cancer phenotype [8]. On the other hand,
a “functional” diagnostic based on proteomics may serve
as a useful complementary tool by providing the most
direct link to the phenotype of cancer cells [9]. As most
targeted agents are signaling modulators, a proteomicsbased diagnostic that can inform the biological effect
of targeted agents in real-time within the tumor will
be extremely helpful in assessing treatment response,
identifying potential resistance mechanisms and guiding
further treatment decision, all of which are impossible
using archived tumor samples.
In this study, we report the use of a multiplex
proteomic-based assay, Collaborative Enzyme Enhanced
Reactive-immunoassay (CEERTM), that is clinically
feasible, highly sensitive and specific. This platform
was previously shown to be successful in detecting
rare “HER2-activated” circulating tumor cells in
HER2-negative metastatic breast cancer patients [10],
indicating its high sensitivity and ability to provide
potentially actionable information beyond the genomic
and transcriptomic levels. We show that the CEER™
platform allows simultaneous detection of the abundance
and activation status of multiple key signaling molecules
(or “markers”) that are uniquely deregulated in PDAC
but not in normal tissues obtained from fine-needle
aspirations (FNA), indicating high specificity and
sensitivity. Encouragingly, while correlating the intensity
of each marker to prognosis we found high c-MET signal
in FNA specimens to be associated with poor prognosis,
which is consistent with published literature based on
immunohistochemistry of resected specimens, indicating
great potential of this platform in studies of advanced,
inoperable PDAC tumors in the future. Finally, we
identified markers with previously unreported prognostic
significance that may unveil novel understanding to PDAC
biology.

Washington University School of Medicine and the
affiliated Siteman Cancer Center (Figure 1A). Besides
obtaining specimens needed to establish a histologic
diagnosis, two additional FNA passes from the same
tumor were collected for CEERTM analysis. A cytological
diagnosis of adenocarcinoma was initially made in 75
patients. However, one patient was later diagnosed
with lung adenocarcinoma with pancreatic metastasis
and another had extrahepatic cholangiocarcinoma with
invasion to the pancreatic head. We excluded three other
patients with PDAC who were lost to follow up from our
institution. On the other hand, 13 patients had negative
cytology, i.e. no evidence of malignant cells were detected
from the initial cytological analysis. Three of these
patients were later excluded after repeat biopsy showed
malignancies including lymphoma, cholangiocarcinoma
and pancreatic adenocarcinoma. Finally, five FNA
samples showed neuroendocrine tumor and another nine
were indeterminate due to insufficient tissue material. In
summary, we focused our analyses on the 70 confirmed
PDAC specimens with complete clinical follow up, and
10 specimens with negative (or non-cancerous) cytology
(Figure 1A). These cytopathologic diagnoses of these ten
negative samples were: 2 normal lymphoid content, 1
cystic content with bland epithelium, 5 benign pancreatic
elements with reactive inflammatory elements, 2 nondiagnostic with scant cellularity.
Characteristics of all 102 patients and the 70 PDAC
patients are provided in Table 1. For CEERTM analysis, all
FNA samples were collected and immediately processed
to maximally preserve the phosphorylation status of each
marker (Figure 1B). A total of 18 markers were assayed in
the CEERTM platform (see Material and Methods section
and Table 2). All 70 patients were treated at Washington
University School of Medicine and followed for up to five
years or until death.

Comparison of different FNA passes and between
negative and positive PDAC samples
We first compared whether the signal intensities of
each marker varied between the two FNA passes from
each patient. As shown in Table 2, we observed modest
to moderate degrees of consistency (Spearman’s rho
coefficients 0.32~0.59) in the signal intensity between
both passes across all markers. This result is highly
reflective of the known low cellularity and potentially
high intratumoral heterogeneity of PDAC tumors [3,
11], underscoring the need to obtain more than one pass
for better representation of the whole tumor. To better
represent tumor cell signaling, the FNA pass with higher
level of cytokeratin (CK), a specific marker for epithelial
cells [12], was used in subsequent analyses.
To determine specificity, we next compared the
intensity of each marker between the 70 PDAC and 10

RESULTS
Patient characteristics
Between year 2010-2012, 102 patients with
radiographic suspicion of pancreatic tumor underwent
endoscopic ultrasonography (EUS) and fine-needle
aspiration (FNA) of the primary pancreatic mass at
www.impactjournals.com/oncotarget
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Figure 1: A. Flow diagram summarizing workflow of all analyses performed and reasons for inclusion and exclusion of subject for CEER

studies. B. Representative images of CEERTM arrays obtained from two FNA passes (#1 and #2) of three patients. Signal intensities ranges
from dark (low) to bright white (high).
www.impactjournals.com/oncotarget
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Table 1: Characteristics of patients enrolled into studies
Characteristics

All patients (N=102)

Confirmed PDAC, evaluable
(N=70)

Median Age (range)
≤ 65
> 65

67.5 (38-89)
45 (44%)
57 (56%)

69.5 (38-89)
29 (41%)
41 (59%)

Gender (All)
Male
Female

53 (52%)
49 (48%)

34 (48.5%)
36 (51.5%)

Race
Caucasian
Non-Caucasian

89 (87.2%)
13 (12.8%)

60 (85.7%)
10 (14.3%)

Location of tumor
Head
Non-head
Tumor size (mm), median (range)

57 (55.9%)
45 (44.1%)
29 (17-70)

38 (54.3%)
32 (45.7%)
29 (13-70)

Final cytopathologic diagnosis
PDAC
Neuroendocrine
Indeterminate
Negative
Other cancer

74 (72.5%)
6 (5.9%)
9 (8.9%)
10 (9.8%)
3 (2.9%)

Initial Clinical Staging
Resectable
Borderline resectable/locally advanced
Metastatic

12 (17.1%)
37 (52.9%)
21 (30%)

Treatment
Surgery
No surgery (chemo ± radiation)

13 (18.5%)
57 (71.5%)

Prognostic significance of measured markers

negative specimens (Table 3). First, we noted significantly
higher CK signals in PDAC samples, compared to negative
samples (p = 0.002), indicating presence of neoplastic
epithelial content in PDAC samples. Remarkably, we
also noted significantly higher signal intensities in several
markers in PDAC samples. These include p-HER2 (p =
0.007), p-HER3 (p = 0.026), total HER2 (p = 0.006), total
HER3 (p = 0.008), total c-MET (p < 0.001), total IGFR
(p = 0.012), p-AKT (p = 0.046), p-ERK1/2 (p < 0.001)
and p-PRAS40 (p = 0.043). In addition, a trend towards
increased p-c-MET (p = 0.051) in PDAC was seen. Of
these markers, total c-Met and p-ERK1/2 signals showed
the strongest statistical difference between PDAC and
negative samples (both p < 0.001), resonating previous
reports that c-MET and p-ERK1/2 immunohistochemical
staining to be markedly elevated in resected PDAC
samples compared to normal pancreas [13-15]. In
addition, the stronger p-ERK1/2 signal in PDAC samples
is consistent with these kinases being key substrates
that are activated downstream of mutant KRas protein,
which is present in almost all PDAC [16, 17]. Overall,
these results demonstrate that the CEERTM technique is a
robust, highly sensitive and specific tool that is capable
of detecting salient signaling aberrations from the FNA
specimens of PDAC patients.
www.impactjournals.com/oncotarget

Apart from having different intensities between
PDAC and negative samples, we also noted wide patientto-patient variation in intensities of all biomarkers, as
discerned by the high standard deviations relative to
the mean values of each marker (Table 3). Therefore,
we hypothesize that the intensity of each marker, which
represents the activity of various signaling pathways,
may reflect the biology of the tumor and hence
patient prognosis. Particularly, since the prognostic
significance of some of these biomarkers, including
c-Met, p-AKT and p-ERK1/2 have been published using
immunohistochemical analyses of resected tumor samples,
which arguably is the “gold standard” technique, we
reasoned that being able to recapitulate similar findings
using FNA specimens would, to some extent, validate the
accuracy of this novel technique and substantiate its utility
in future clinical application, particularly for most PDAC
patients with inoperable disease where large amount of
tumor specimen is not available. To this end, we followed
all 70 PDAC patients for up to five years or until death.
We divided all 70 PDAC patients into two survival groups
(≤ or > median), using overall median survival (11.5
24253
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Table 2: Spearman correlation coefficients of each marker between two passes

months, range 0.2 months ~ 5 years) as a cut-off (Table 4).
When markers between these two survival groups were
compared, we found that tumors associated with poor
survival had a strong trend towards having higher total
c-MET level compared to those with better survival (p =
0.05), resonating previous report showing c-MET to be
frequently overexpressed and represents an independent
poor prognostic factor in resected PDAC patients [18, 19].
Interestingly, patients with poor survival had significantly
lower levels of p-SHC (p = 0.002), p-PRAS40 (p = 0.002)
and p-AKT (p = 0.025). Partly resonating this finding,
another study also showed that high p-AKT IHC staining
in resected PDAC samples was associated with better
patient prognosis [20].
Besides these biomarkers, clinical parameters
such as clinical stage (including tumor size and lymph
node status), tumor grade, age at diagnosis, medical
comorbidities all have significant prognostic implication in
PDAC patients. All these individual parameters culminate
into a composite decision of surgical resection, which
to date is the single most important prognostic factor in
the outcome of PDAC patients [21]. Of all 70 PDAC
patients we analyzed, patients who underwent curative
resection (N = 13, or 18.6%) had a median survival of
20.8 months (range 5.1 months ~ alive at 46 months)
compared to 8.2 months (range 0.2~33 months, all died)
for those who could not be resected (N = 57, or 81.4%,
Wilcoxon p = 0.003). Among these 70 patients, we did not
detect statistically significant differences in survival based
on age, tumor size, nodal status, stage, or tumor grade,
www.impactjournals.com/oncotarget

probably due to small sample size and the fact that most
patients were diagnosed at inoperable stages. Of the 57
non-operable patients, patients with locally-advanced (N
= 37) or metastatic disease (N = 20) had a median OS
of 9.7 and 6.7 months respectively, which did not reach
statistical significance (Wilcoxon P = 0.36) probably due
to small sample size and the inherent aggressive nature of
this disease.
We next explored the prognostic impact of each
marker among the inoperable patients (N = 57), which
is rarely reported in the literature due to the limited
availability of PDAC tissues from these patients. By
focusing on these patients, we believe we could more
accurately capture the biological role of each marker in
the natural progression of PDAC without the dramatic
interference of surgical removal. Therefore, any markers
later found to have prognostic impact could have a
larger therapeutic implication in the future as most
PDAC patients are either diagnosed at, or eventually
will progress to, advanced stage. To this end, we divided
all 57 patients into two groups using median OS (8.2
months) as a cut-off, and compared the intensity of all
markers between these two groups (Table 4). Again, we
found that patients will poorer prognosis had significantly
higher expression levels of total c-MET (p = 0.027).
Interestingly, these patients also had significantly higher
levels of p-SHC and p-PRAS40 (p = 0.006 and p = 0.032,
respectively). Importantly, patients with poorer prognosis
were significantly older (mean 72.4 years old) compared
to those with better prognosis (mean 64.5 years old, p =
24254
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Table 3: Comparison of overall marker intensities between negative vs PDAC specimens

0.018), consistent with published literature showing older
age as a poor prognostic marker [22].

supporting targeting c-MET to improve the outcome for
PDAC patients. Overall, our results further substantiate
the quantifying power of the CEERTM platform, rendering
it extremely useful in future clinical trial design.

Independent validation of prognostic significance
of c-MET using PDAC tissue microarray

DISCUSSION

While the robust quantitative capability of the
CEERTM platform has enabled prognostication to be
ascribed to certain markers such as total c-Met, p-SHC
and p-PRAS40, further validation is needed. First, high
level of c-MET immunohistochemical staining in resected
PDAC tumors has already been reported by different
groups to be a poor prognostic marker [18, 19]. Second,
to further confirm this finding, we performed c-MET IHC
staining on an independent PDAC tissue microarray built
at our institution. Using the MetMab visual IHC scoring
criteria (0 to 3+) that is widely adopted [23, 24] (Figure
2A), we found that the overall expression of c-MET is high
(MetMab IHC score 2+ or 3+) in 53 out of 140 samples (or
37.9%) of all PDAC samples. Consistent with our findings
from the CEERTM platform, high c-MET IHC score is
associated with poor prognosis in this independent cohort
of patients (p = 0.03) (Figure 2B). On further analysis of
PDAC samples, we indeed found significant correlation
between the intensities of total and phospho-c-MET
signals (Spearman r 0.64, p < 0.0001; Figure 2C), further
www.impactjournals.com/oncotarget

Development of a powerful “functional” diagnostic
is direly needed to monitor treatment response in the era
of targeted therapy. The described CEERTM platform is
particularly powerful in many aspects. First, this platform
provides, in addition to expression levels, activation status
of multiple key signaling molecules, which is impossible
with current transcriptomic or genomic techniques. In
PDAC, inhibitors that target the key KRas effectors such
as the Raf-MEK-ERK and PI3K-AKT-mTOR pathways
are being actively pursued in clinical trials, albeit with
little success due to rapid emergence of various different
resistance mechanisms including kinome reprogramming
[26]. While these mechanisms can be readily identified,
and overcome using cultured cells in the lab, being able
to do so in the clinic in real time is essential in initial
clinical trial allocation, and informing combinatorial
strategies if no response is seen. To this end, the CEERTM
technique could potentially provide a comprehensive,
quantifiable signaling changes across multiple signaling
pathways within the tumor tissues before and after
24255
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Table 4: Prognostic significance of age and tested markers in PDAC patients
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therapeutic intervention. Second, the ultra-sensitivity
of this platform allows analysis to be performed using
scant amount of tissues such as FNA samples, which
is especially attractive for clinical trials on pancreatic
cancer, where tissues are limited and prone to degradation
by catalytic enzymes in the pancreas. Third, the CEERTM
platform provides clear proteomic distinction between
normal pancreatic and PDAC tissues, indicating robust
specificity. For instance, significantly higher signal
intensity of EGFR/HER signaling, total c-MET, total
IGFR, p-AKT, p-ERK1/2 and p-PRAS40 were seen in
PDAC compared to non-cancerous samples. Of these
markers, enhanced phosphorylation of ERK1/2, AKT
and PRAS40 are all known events driven by the KRas
oncoprotein. Therefore, these markers could serve as
readouts in clinical trials for various inhibitors against the
KRas effectors. Forth, processing of tumor specimens and
data analysis are relatively less sophisticated than genomic
or transcriptomic tools, which will diminish both cost and
turnaround time. In summary, all these advantageous
features render the CEERTM technique an extremely
attractive companion diagnostic in future clinical trial
design.

An important finding from analyzing the result
from CEERTM is the wide patient-to-patient variability
in the signal intensity of each marker. This finding is
reflective of the highly heterogeneous biology of PDAC,
as supported by discovery of various molecular subtypes
of PDAC based on genomic and transcriptomic analyses
[2-4]. On this basis, the CEERTM platform may be able
to provide essential complementary proteomic data that
could aid treatment selection and even prognostication.
Supporting this notion, we showed that high level of
c-MET expression by CEERTM is associated with inferior
survival for patients with advanced inoperable PDAC.
We validated this data by immunohistochemistry, which
is the most widely accepted technique. In addition, the
poor prognostication of high c-MET level in PDAC has
also been published in retrospective analysis [19], and
preclinical studies also show that activation of c-MET in
PDAC can enhance proliferation, survival, invasiveness,
and treatment resistance [14, 25]. Several c-MET
inhibitors are being evaluated in clinical trials for various
cancer types including PDAC, with promising results still
lacking, presumably due to poor patient selection and de
novo resistance [27]. Biomarkers to predict response such

Figure 2: Independent validation of prognostic significance of total c-MET IHC staining in PDAC tissue microarray
from another cohort of 140 patients. A. Representative IHC images showing various assigned intensity of total c-MET staining in

PDAC tissue microarray. B. Kaplan-Meier survival analysis of patients based on c-MET IHC score. C. Spearman correlation between total
and phospho-c-MET signals of FNA samples subject to CEERTM.
www.impactjournals.com/oncotarget
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as circulating HGF or c-MET levels, c-MET genomic
amplification or protein overexpression are being assessed.
To this end, the CEERTM technique could certainly provide
pre-treatment levels of total and activated c-MET to aid
patient selection, and importantly, assessment of ontarget effect and potential escape mechanisms at treatment
failure.
Intriguingly, our data showed that high
phosphorylation of SHC and PRAS40 proteins to be
associated with better prognosis in PDAC patients, which
have not been reported. In contrast, high p-SHC correlates
with aggressive features and poor prognosis in gastric
and breast cancer [28, 29], which underscores caution
when extrapolating research data from one cancer type
to another. The SHC proteins consists of three different
splicing isoforms, p46shc, p52shc and p66shc, and are
all members of the Src homologous- collagen homologue
adaptor protein family that have very divergent roles in
regulating signal downstream of growth factor receptors
[30]. Since the antibody used in our CEERTM platform
recognizes all three SHC isoforms, development of
isoform-specific phospho-SHC antibodies will be
invaluable in informing the prognostic implication of
each isoform and provide novel therapeutic opportunities.
Similarly, the association of higher p-PRAS40 with better
survival in PDAC is also different from a study in gastric
cancer, where presence of p-PRAS40 was associated with
aggressive histologic features and poor prognosis [28].
The proline-rich AKT substrate of 40-kDA (PRAS40)
is a substrate of AKT which functions as an inhibitor to
mTORC1 complex in regulating glucose metabolism
[31, 32] . To date, the role of PRAS40 in PDAC is
largely unclear and should be investigated. Overall, these
interesting observations underscore the ability of the
CEERTM in revealing, in an unbiased manner, novel and
potentially important clues that can be pursued.
There are a few limitations in our study. First, low
tumor cellularity and tumor heterogeneity remain concerns
especially in PDAC. Although we focused our analyses
on the FNA sample that has the higher CK value, signals
from stromal and immune cells may interfere with the
readouts we obtained. In future studies, more FNA passes
should be obtained for analysis of the sample with the
highest CK value. Second, we are unable to determine the
prognostic impact of different chemotherapeutic regimens
on patient survival due to small patient number (N = 57).
However, all patients received systemic treatment per the
NCCN guidelines, which include 5-FU or gemcitabinebased chemotherapy regimens as standard-of-care or part
of clinical trials. Larger studies in the future are needed
to confirmed the prognostic impact of individual markers
examined in our present study.
In conclusion, we demonstrate, for the first time in
literature successful utilization of an unbiased, proteomicbased functional diagnostic that allows comprehensive
elucidation and quantification of signaling aberrations in
www.impactjournals.com/oncotarget

primary PDAC tumors. We demonstrate that this technique
is clinically feasible, highly sensitive, specific and reliable.
In the current era of precision oncology when the use of
kinase inhibitor is increasingly frequent, this technique
could provide irreplaceable proteomic information
within the tumor, which could be critical in assessing
the treatment effect and providing secondary signaling
changes that could inform resistance mechanisms. As
such, we believe this technique has irreplaceable value,
in complement to genomic and transcriptomic tools, in
realizing the goals of personalized oncology.

MATERIALS AND METHODS
Tumor specimen procurement
Tumor specimens were prospectively collected via
endoscopic ultrasound-guided fine needle aspiration (EUSFNA) from 102 patients presenting with a suspicious
pancreatic mass as summarized in Figure 1A. Informed
consent, specimen collection and future data collection
were all conducted under IRB approval (Washington
University in St. Louis IRB protocol #201106347). In
addition to the passes obtained for routine clinical care,
two EUS-FNA passes were performed and immediately
collected in separate vials containing 100 μl of
preservation and lysis solution (proprietary information,
Prometheus Laboratories Inc.). The resulting lysates were
shipped to Prometheus Laboratories (San Diego, CA) at
ambient temperature within 48 hours of sample collection,
and stored at -70oC upon receipt until subsequent CEERTM
analysis.

Collaborative enzyme
immunoassay (CEERTM)

enhanced

reactive

To measure the expression and activation levels
of receptor tyrosine kinases and signal transduction
proteins in clinical specimens, we employed CEERTM,
a highly sensitive multiplexed immunoarray platform.
Detailed methods for this technology have been described
previously [1-5]. Briefly, capture antibodies (Abs) were
printed on nitrocellulose-coated glass slides (ONCYTER
Grace Biolabs) using a non-contact printer (Nano-Plotter,
GeSiM). The spot diameter was approximately 175 μm
and printed slides were kept in a desiccated chamber at
room temperature. Capture Abs were printed in triplicate
and at serial dilution concentrations of 1 mg/mL and 0.5
mg/mL. Purified mouse-IgGs served as negative controls.
Immunoarray slide configurations and assay format
were performed as previously described [1-5]. Briefly,
immunoarray slides were rinsed with TBST (50 mM
Tris/ 150 mM NaCl/ 0.1% Tween-20, pH 7.2-7.4) and
blocked for 1 hour at room temperature (RT). Serially
24258
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diluted lysate controls in 80 µL dilution buffer (2% BSA/
0.1% TritonX-100/ TBS, pH 7.2-7.4) and samples were
added to designated sub-arrays on slides, then incubated
overnight at RT. After several washes, slides were
incubated with two detector Abs (for different epitopes)
conjugated with glucose oxidase (GO) and horseradish
peroxidase (HRP) respectively for 2 hours at RT. After
washing slides with TBST to remove unbound detector
Abs, GO/HRP-mediated tyramide signal amplification
process was triggered by adding biotin-tyramide solution
and incubating for 30 mins. Local deposition of biotintyramide was detected by incubation with streptavidinAlexa Fluor647 (Life Technologies, Carlsbad, CA)
for 40 min. Slides were washed with TBST, dried and
immediately processed on a high-resolution fluorescence
microarray scanner (PowerScanner, Tecan). Backgroundcorrected signal intensities were averaged for capture
antibodies printed in triplicate. For each marker, a
standard curve was generated from serially diluted control
lysates prepared from specific cell lines. HCC827, a
NSCLC adenocarcinoma cell line carrying EGFR gene
amplification and exon 19 deletion, was used for EGFR
and MET quantifications, while breast cancer cell lines
BT474 and T47D, served for HER2/PRAS40/RPS6 and
HER3/IGF1R/PI3K/CK quantifications respectively.
Alternatively, standard curves were generated from
serially diluted recombinant proteins for AKT, ERK, MEK
and RSK assays. Each curve was plotted as a function of
signal intensity measured as relative fluorescence unit
(RFU) vs. log concentration of cell lysates/ recombinant
proteins or Computed Unit (CU). The data were fit
to a five-parameter equation by nonlinear regression,
simultaneously fitting both dilutions of the capture Ab as
described previously [10, 33]. CEER measurements are
determined in Computed Unit (CU). CU is a representation
of marker expression/ activation in unknown samples
relative to that of control cell lines with known expression
/activation levels. Hence, a sample with 1 CU of HER1
expression has an RFU value equivalent to 1 standard
reference HCC827 cell. Because expression and activation
of each marker is determined in unique CEER™ assays
with different cell line standards, only CU values of the
same marker across various samples can be compared.

cooker. Sections were incubated at 4ºC overnight with
total c-MET antibody (D1C2, Cell Signaling Technology,
1:200), followed by staining using the DAB Peroxidase
(HRP) Substrate Kit with Nickel (Vector Laboratories
cat#SK-4100). Stained slides were digitalized and scored
independently by a GI pathologist (D.C) in blinded fashion
using the MetMab IHC scoring method as published [23,
24]. Briefly, stained tumors were scored between 0-3+
based on : 0: no staining or < 50% of tumor cells with any
intensity; 1+: ≥ 50% of tumor cells with weak or higher
intensity but < 50% with moderate or higher intensity; 2+:
≥ 50% of tumor cells with moderate or higher intensity
but < 50% with strong intensity; 3+: ≥ 50% of tumor cells
staining with strong intensity).

Statistical analysis
Due to the presence of detecting limits, all the
measured markers were analyzed using non-parametric
tests which were based on relative ranks rather than
absolute values. The correlation between two FNA passes
from the same patients were assessed using Spearman
correlation coefficient. In subsequent analysis, the FNA
pass with higher cytokeratin (CK) level was retained for
data analysis. The difference in each marker between
positive and negative PDAC samples was compared using
Mann-Whitney rank-sum test. Among these 70 patients
with positive PDAC, only 2 patients (who happened to
have the longest follow-up times) were censored and the
survival times were observed in all other patients. To
assess the prognostic value of each marker on survival,
the patients were categorized into 2 groups by median
survival time, and the between-group difference in
each marker was then compared using Mann-Whitney
rank-sum test. The survival curves by other clinical
characteristics such as stage and grade were also estimated
using Kaplan-Meier product limit method. Since almost
all the patients died during follow-up and the estimated
survival curves were more likely to converge eventually,
the difference between survival curves were compared by
Gehan-Breslow-Wilcoxon (Wilcoxon) method (which is
less sensitive to the proportional hazard assumption). All
the tests were two-sided with p-value of 0.05 indicating
significance. The data was analyzed using the standard
package of SAS (Version 9.3, SAS Institute, Cary, NC).

Pancreatic
cancer
TMA,
c-Met
immunohistochemistry (IHC) and scoring
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